BBIO NASDAQ
BridgeBio Pharma, Inc.
1W: +2.7%
1M: +4.1%
3M: -17.0%
YTD: -11.3%
1Y: +27.9%
3Y: +182.3%
5Y: +47.1%
$69.37
+1.22 (+1.79%)
Weekly Expected Move ±3.8%
$63
$66
$69
$71
$74
Credit Risk of going bust: lower than 52% of companies Debt: 15.5% of company value Bonds: $309.3M held by 77 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.42 (down 98%), BridgeBio Pharma, Inc. would be worth roughly what it owes.
Total debt $2.49B against a stock market value of $13.56B.
Distance to default 5.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.51B (short-term plus half of long-term), stock volatility 46.4%; Altman Z'' -14.10. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.42 (down 98%), BridgeBio Pharma, Inc. would be worth roughly what it owes.
Total debt $2.49B against a stock market value of $13.56B.
Distance to default 5.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.51B (short-term plus half of long-term), stock volatility 46.4%; Altman Z'' -14.10. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships18
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2022-05-13
Earliest Filing
2025-07-02
Latest Filing
investor: 9
partner: 8
JV: 1
Counterparties (Filed by BBIO)
18 relationshipsCompanies named in BBIO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Eidos Therapeutics, Inc. | — | partner | Subsidiary of BridgeBio Pharma, Inc. that entered into the Royalty Interest Purchase and Sale Agreement. | 2025-07-02 | View |
| Acoramidis Royalty SPV, LP | — | investor | Purchaser representative in the Royalty Interest Purchase and Sale Agreement. | 2025-07-02 | View |
| LSI Financing Fund, LP | — | investor | Purchaser in the Royalty Interest Purchase and Sale Agreement. | 2025-07-02 | View |
| Bayer Consumer Care AG | — | partner | Licensee under the Bayer License Agreement granting rights to sell Licensed Products. | 2025-07-02 | View |
| GondolaBio | — | JV | Joint venture formed to research, develop, and commercialize pharmaceutical products | 2024-08-21 | View |
| Viking Global Investors LP | VIK | investor | Investor providing tranched financing to GondolaBio | 2024-08-21 | View |
| Patient Square Capital | — | investor | Investor providing tranched financing to GondolaBio | 2024-08-21 | View |
| Sequoia Capital | — | investor | Investor providing tranched financing to GondolaBio | 2024-08-21 | View |
| Frazier Life Sciences | — | investor | Investor providing tranched financing to GondolaBio | 2024-08-21 | View |
| Cormorant Asset Management | — | investor | Investor providing tranched financing to GondolaBio | 2024-08-21 | View |
| Aisling Capital | — | investor | Investor providing tranched financing to GondolaBio | 2024-08-21 | View |
| Neil Kumar | — | investor | Entity owned by CEO Neil Kumar providing financing to GondolaBio | 2024-08-21 | View |
| Goldman Sachs & Co. LLC | GSCE | partner | Sales agent for at-the-market offering program | 2023-05-04 | View |
| Jefferies LLC | JEF | partner | Former sales agent for terminated Open Market Sales Agreement | 2023-05-04 | View |
| Navire Pharma, Inc. | — | partner | Counterparty to the License, Development and Commercialization Agreement referenced in the prepayment acknowledgment | 2022-12-06 | View |
| Bristol-Myers Squibb Company | — | partner | Counterparty to the License, Development and Commercialization Agreement referenced in the prepayment acknowledgment | 2022-12-06 | View |
| Origin Biosciences, Inc. | — | partner | Affiliate that received FDA approval for NULIBRY leading to the pediatric review voucher award | 2022-05-18 | View |
| Bristol-Myers Squibb Company | — | partner | Exclusive license agreement for Navire's product candidate BBP-398 | 2022-05-13 | View |
Mentioned As Counterparty
1 mentionsOther companies that named BBIO in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-13 | Other Events; Exhibits | View | |
| 2026-08-31 | Other Events; Exhibits | View | |
| 2026-08-17 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-07-22 | Other Events; Exhibits | View | |
| 2026-07-02 | Material Agreement; Unregistered Equity Sales; Bylaws Amendment; Regulation FD; Exhibits | Agreement | View |
| 2026-06-26 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-27 | Other Events; Exhibits | View | |
| 2026-05-13 | Other Events; Exhibits | View | |
| 2026-05-08 | Material Agreement; Termination of Agreement; Exhibits | Agreement | View |
| 2026-05-07 | Earnings Release; Other Events | View | |
| 2026-03-30 | Other Events; Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-12 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-21 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-10-29 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-27 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR